Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6QMT

Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid

Summary for 6QMT
Entry DOI10.2210/pdb6qmt/pdb
Related6QMR
DescriptorComplement factor D, 2-[2-[[3-[3-(aminomethyl)phenyl]phenyl]carbonylamino]phenyl]ethanoic acid (3 entities in total)
Functional Keywordscomplement factor d, inhibitor, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight54916.68
Authors
Primary citationKarki, R.G.,Powers, J.,Mainolfi, N.,Anderson, K.,Belanger, D.B.,Liu, D.,Ji, N.,Jendza, K.,Gelin, C.F.,Mac Sweeney, A.,Solovay, C.,Delgado, O.,Crowley, M.,Liao, S.M.,Argikar, U.A.,Flohr, S.,La Bonte, L.R.,Lorthiois, E.L.,Vulpetti, A.,Brown, A.,Long, D.,Prentiss, M.,Gradoux, N.,de Erkenez, A.,Cumin, F.,Adams, C.,Jaffee, B.,Mogi, M.
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
J.Med.Chem., 62:4656-4668, 2019
Cited by
PubMed Abstract: Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria. Previously, we have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (1 and 2) binding to the open active conformation of FD. In continuation of our drug discovery program, we designed compounds applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases. We report herein the design, synthesis, and medicinal chemistry optimization of the benzylamine series culminating in the discovery of 12, an orally bioavailable and selective FD inhibitor. 12 demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
PubMed: 30995036
DOI: 10.1021/acs.jmedchem.9b00271
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon